Any feedback?
Literature summary for 3.4.11.3 extracted from
- Plasma oxytocinase: the synthesis and biological properties of the first product of the degradation of oxytocin by this enzyme (1974), Can. J. Biochem., 52, 60-66.
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| 1,2-Acyclic oxytocin | slight inhibition of oxytocin degradation, marked inhibition of cystine di-beta-naphthylamide degradation | Homo sapiens |  |
KM Value [mM]
| KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|
| additional information | - |
additional information | - |
Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
produced during pregnancy | - |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| plasma | - |
Homo sapiens | - |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| oxytocin + H2O | - |
Homo sapiens | acyclic peptide + H2O | tyrosyl-isoleucyl-glutaminyl-asparaginyl-S-(S-cysteine)cysteinyl-prolyl-leucyl-glycinamide, first product | ? | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
